Literature DB >> 29269998

Endoscopic Eradication Therapy in Barrett's Esophagus.

Swathi Eluri1, Nicholas J Shaheen1.   

Abstract

Endoscopic eradication therapy (EET), the standard of care for treatment of Barrett's esophagus with dysplasia and early neoplasia, consists of a combination of endoscopic resection and ablative modalities. Resection techniques primarily include endoscopic mucosal resection or endoscopic submucosal dissection. Resection of nodular disease is generally followed by one of multiple ablative therapies among which radiofrequency ablation has the best evidence supporting safety and efficacy. These advanced endoscopic procedures require both experience and expertise in the cognitive and procedural aspects of EET. However, very few formal programs exist that teach endoscopists the necessary skills to perform EET in a safe, standardized, and efficacious manner. Case volume at both the endoscopist and center level has been shown to impact clinical outcomes based on limited data. As a result, some recent guidelines endorse case volume as a measure of competency. Quality indicators, which can be used as benchmarks for training and as part of pay for quality initiatives, have recently been derived for EET. However, quality metrics in EET have not been widely accepted, nor are they broadly used currently. While the efficacy of EET for BE is established, there is a need for application of quality metrics to both assure adequate training in these procedures, as well as to assess treatment outcomes. A standardized EET training curriculum during endoscopic training, with competency assessment of both new clinicians and endoscopists in practice has potential to improve care in EET.

Entities:  

Keywords:  Barrett's esophagus; competency assessment; endoscopic eradication therapy; endoscopic training; quality metrics

Year:  2017        PMID: 29269998      PMCID: PMC5733795          DOI: 10.1016/j.tgie.2017.06.001

Source DB:  PubMed          Journal:  Tech Gastrointest Endosc        ISSN: 1096-2883


  43 in total

1.  Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus.

Authors:  David I Fudman; Charles J Lightdale; John M Poneros; Gregory G Ginsberg; Gary W Falk; Maureen Demarshall; Milli Gupta; Prasad G Iyer; Lori Lutzke; Kenneth K Wang; Julian A Abrams
Journal:  Gastrointest Endosc       Date:  2014-02-22       Impact factor: 9.427

2.  Detection and staging of esophageal cancers within Barrett's esophagus is improved by assessment in specialized Barrett's units.

Authors:  Georgina R Cameron; Chatura S Jayasekera; Richard Williams; Finlay A Macrae; Paul V Desmond; Andrew C Taylor
Journal:  Gastrointest Endosc       Date:  2014-06-11       Impact factor: 9.427

3.  Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study).

Authors:  Hendrik Manner; Thomas Rabenstein; Oliver Pech; Kirsten Braun; Andrea May; Juergen Pohl; Angelika Behrens; Michael Vieth; Christian Ell
Journal:  Endoscopy       Date:  2013-12-18       Impact factor: 10.093

4.  Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.

Authors:  C J Kelty; R Ackroyd; N J Brown; T J Stephenson; C J Stoddard; M W R Reed
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

5.  Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus.

Authors:  Katie Ayers; Chanjuan Shi; Kay Washington; Patrick Yachimski
Journal:  Surg Endosc       Date:  2013-02-07       Impact factor: 4.584

6.  Variations between endoscopists in rates of detection of colorectal neoplasia and their impact on a regional screening program based on colonoscopy after fecal occult blood testing.

Authors:  Jean-François Bretagne; Stéphanie Hamonic; Christine Piette; Sylvain Manfredi; Emmanuelle Leray; Gérard Durand; Françoise Riou
Journal:  Gastrointest Endosc       Date:  2009-11-17       Impact factor: 9.427

7.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

9.  The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection.

Authors:  Sheraz R Markar; Hugh Mackenzie; Melody Ni; Jeremy R Huddy; Alan Askari; Omar Faiz; S Michael Griffin; Laurence Lovat; George B Hanna
Journal:  Gut       Date:  2016-10-18       Impact factor: 23.059

10.  A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia.

Authors:  Grischa Terheggen; Eva Maria Horn; Michael Vieth; Helmut Gabbert; Markus Enderle; Alexander Neugebauer; Brigitte Schumacher; Horst Neuhaus
Journal:  Gut       Date:  2016-01-22       Impact factor: 23.059

View more
  1 in total

Review 1.  Management of Barrett's esophagus with dysplasia refractory to radiofrequency ablation.

Authors:  Kara L Raphael; Arvind J Trindade
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.